Related Experiment Video
Updated: Jun 27, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
[Sparfloxacin in combined therapy for pulmonary tuberculosis]
Abstract:
Efficacy and safety of the difluoroquinolone sparfloxacine used in combined therapy for drug-succeptible and drug-resistant pulmonary tuberculosis were studied. Clinical trials enrolled 60 patients with severe pulmonary tuberculosis. The most effective combinations of sparfloxacine and other antituberculous drugs were determined. Data on satisfactory tolerability of sparfloxacine used in various combinations of the main and reserve agents are presented.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
